Royalty Pharma targets $3B share buyback and projects 4-9% growth in 2025 portfolio receipts
Q4 2024 Management View CEO Pablo Legorreta highlighted strong 2024 performance, reporting $2.8 billion in portfolio receipts, at the high end of guidance and reflecting 13% growth in Royalty Receipts ...